Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

IIROC Trade Resumption - BHC

Canada NewsWire July 28, 2022

IIROC Trading Halt - BHC

Canada NewsWire July 28, 2022

IIROC Trade Resumption - BHC

Canada NewsWire July 28, 2022

Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9

PR Newswire July 27, 2022

Bausch + Lomb Provides Leadership Update

PR Newswire July 20, 2022

Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

PR Newswire July 13, 2022

Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors

PR Newswire June 23, 2022

Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation

PR Newswire June 21, 2022

Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2022

PR Newswire June 20, 2022

Bausch Health Provides Update on Solta Medical

PR Newswire June 16, 2022

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

PR Newswire May 18, 2022

Bausch Health Announces Participation In Upcoming Investor Conferences

PR Newswire May 11, 2022

Bausch Health (TSX:BHC) sees dip in growth but stays stable

Caroline Egan  May 10, 2022

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

PR Newswire May 10, 2022

Bausch Health Companies Inc. Announces First-Quarter 2022 Results

PR Newswire May 10, 2022

Bausch Health Announces Thomas J. Appio As Chief Executive Officer

PR Newswire May 6, 2022

Bausch + Lomb Corporation Announces Pricing of IPO

Canada NewsWire May 5, 2022

Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting

PR Newswire May 3, 2022

Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10

PR Newswire April 29, 2022

Bausch + Lomb Corporation Announces Launch of IPO and Roadshow

PR Newswire April 28, 2022